Figure 1



Figure 2A



Figure 2B



Figure 3



Figure 4A



Figure 4B



Figure 5



Figure 6


C
D
B
A
G
C
D
B
A
2840
2830
2820
2810
2800
2790
2780
2770
2760
100
90
80
70
60
50
40
30
20
10
0

Figure 7


Viability [ATP RLU]
5000000
4000000
3000000
2000000
1000000
untreated
tetrameric anti-Her2
dimeric anti-Her2
trastuzumab
0,01
0,1
1
10
100
1000
Antibody [nM]

Figure 8A


RU
160
140
120
100
80
60
40
20
0
-20
-100
0
100
200
300
400
500
600
Response (0 = capture_baseline)
Time (0 = capture_baseline)
s
dimeric anti-Her2
tetrameric anti-Her2
anti-digoxigenin
trastuzumab

Figure 8B


RU
300
250
200
150
100
50
0
-50
Response (0 = capture_baseline)
-100
0
100
200
300
400
500
600
Time (0 = capture_baseline)
s
dimeric anti-Her2
tetrameric anti-Her2
anti-digoxigenin
trastuzumab

Figure 9

A)


100,00
80,00
60,00
40,00
20,00
,00
-20,00
% ADCC
0,01
0,1
1
10
100
nM
dimeric anti-Her2
tetrameric anti-Her2
trastuzumab

B)


120,00
100,00
80,00
60,00
40,00
20,00
,00
-20,00
% ADCC
0,01
0,1
1
10
100
nM

Figure 10



Figure 11

A



B



Figure 12



Figure 13



Figure 14



Figure 15


mAU
550
500
450
400
350
300
250
200
150
100
50
0
35
40
45
50
55
60
65
70
75
80
85
90
ml
1.A2
1.A4
1.A6
1.A8
1.A10
1.A12
1.B2
1.B4
1.B6
1.B8
1.B10
1.B12
1.C2
1.C4
1.C6
1.C8
Waste1F